A shRNA, its recombinant expression vector, transformant, anti-heart failure drug, preparation method and pharmaceutical use
By developing a recombinant adeno-associated virus delivery system, the shRNA-AHF sequence was inserted into the recombinant plasmid, which solved the problem of the immunogenicity and short expression time of existing gene therapy vectors in the treatment of heart failure, and achieved the effect of significantly improving heart function. Fill in the gaps in the treatment of heart failure.
Patent Information
- Application Number
- CN202310137487.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-17
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-02-17
AI Technical Summary
Existing gene therapy vectors such as adenovirus and lentiviruses have problems with immunogenicity and short expression time in the treatment of heart failure, and small RNA drugs have not been widely used in clinical practice.
A small RNA drug rAAV-shRNA-AHF that delivers short hairpin RNA (shRNA) was developed, and the shRNA-AHF sequence was inserted into the recombinant plasmid using the adeno-associated virus expression vector pAAV D(+), and Recombinant adeno-associated viruses were prepared by packaging and co-transfection of three plasmids, which were used to significantly improve cardiac function.
In animal experiments, rAAV-shRNA-AHF significantly improved the heart function of heart failure mice, demonstrating its effectiveness and potential in the treatment of heart failure.
Smart Images

Figure CN116286820B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to shRNA, its recombinant expression vector, transformant, anti-heart failure drug, preparation method and pharmaceutical use. Background Art
[0002] Heart failure is a clinical syndrome in which different cardiovascular diseases develop to the terminal stage. Although some new drugs have been used in clinical practice in recent years, about 50% of heart failure patients still die within 5 years after diagnosis. Heart failure has a poor prognosis and high mortality rate. It is one of the main causes that threaten human health and increase medical burden.
[0003] Currently, adenovirus and lentivirus are mostly used as expression vectors for gene therapy, but lentivirus is mostly modified from leukemia virus or HIV, and adenovirus vectors have a short expression time and are immunogenic to the body, which are not suitable for future clinical applications. Recombinant adeno-associated virus vector (rAAV) overcomes the shortcomings that other gene expression vectors are difficult to overcome, has no immunogenicity, and can drive the target gene to be expressed in the body for a long time, thus becoming the most promising vector for gene therapy.
[0004] Small nucleic acid drugs refer to drugs that can use small nucleic acid molecules such as siRNA, miRNA and antisense nucleic acid ASO to specifically silence the expression of disease genes in order to cure specific diseases. Among them, siRNA refers to double-stranded RNA or hairpin structure RNA (shRNA) that is cleaved by nuclease to form siRNA, which generates sense strands and antisense strands under the action of helicase, and forms RNA-induced silencing complexes to cut and degrade the target gene, thereby inhibiting the expression of the target gene. Currently, many new small RNA drugs have been launched on the market (such as siRNA drug Inclisiran for the treatment of hyperlipidemia, ASO drug casimersen for the treatment of Duchenne muscular dystrophy, etc.), which have great prospects for clinical application. However, small RNA drugs for the clinical treatment of heart failure are still blank.
[0005] In the present invention, the applicant designed and developed a small RNA drug that delivers short hairpin RNA (shRNA) via rAAV, which can significantly improve cardiac function and has the potential to treat heart failure. Summary of the invention
[0006] In view of the above-mentioned problems and shortcomings objectively existing in the field, the inventors developed a small RNA drug rAAV-shRNA-AHF (AHF, anti-heart-failure) that delivers short hairpin RNA (shRNA) via rAAV, and conducted animal experiments to verify its effect. It was found that rAAV-AHF can significantly improve the heart function of mice and treat heart failure.
[0007] The above technical objectives of the present invention are achieved through the following technical solutions:
[0008] A shRNA, characterized in that the corresponding DNA sequence is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0009] The above shRNAs can negatively regulate the myocardial hypertrophy marker ANP, and have the prospect and value of preparing anti-heart failure drugs. Among them, the shRNA of SEQ ID NO.1 has an anti-heart failure effect verified by animal experiments. The corresponding DNA sequence refers to a DNA sequence in which the U base in the shRNA corresponds to the T base, and the other bases are consistent with the shRNA.
[0010] A recombinant expression vector, characterized in that it is an expression vector connected with shRNA; the DNA sequence corresponding to the shRNA is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0011] The promoter of the expression vector is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV;
[0012] Preferably, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
[0013] A transformant, characterized in that it is a host transformed with a recombinant expression vector; the recombinant expression vector is an expression vector connected with shRNA; the DNA sequence corresponding to the shRNA is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0014] The host is selected from: viruses, and / or cells;
[0015] Preferably, the virus is selected from adeno-associated virus;
[0016] Preferably, the cells are selected from 293 cells;
[0017] Preferably, the promoter of the expression vector is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV;
[0018] Preferably, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
[0019] An anti-heart failure drug includes a pharmacologically active ingredient, characterized in that the pharmacologically active ingredient includes: a shRNA whose corresponding DNA sequence is selected from SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0020] The pharmacologically active ingredient is selected from the group consisting of: shRNA, recombinant expression vector, and transformant;
[0021] The shRNA has the sequence shown in SEQ ID NO.1; the transformant is a host containing a recombinant expression vector; the recombinant expression vector is an expression vector connected to the shRNA with the sequence shown in SEQ ID NO.1;
[0022] Preferably, the anti-heart failure drug further comprises: pharmaceutical excipients;
[0023] Preferably, the promoter of the expression vector is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV;
[0024] Preferably, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
[0025] A method for preparing an anti-heart failure drug, characterized in that shRNA is prepared; the DNA sequence corresponding to the shRNA is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0026] The preparation is selected from the group consisting of synthesis, amplification, expression, cloning, secretion, enrichment, and expansion;
[0027] Preferably, the synthesis refers to whole gene synthesis technology;
[0028] Preferably, the cloning refers to connecting the shRNA to an expression vector;
[0029] Preferably, the promoter of the expression vector is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV;
[0030] Preferably, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
[0031] The use of shRNA in preparing an anti-heart failure drug is characterized in that the DNA sequence corresponding to the shRNA is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0032] The present invention provides use of shRNA in preparing medicine for treating heart failure.
[0033] Preferably, the expression vector is an adeno-associated virus expression vector pAAV-D(+);
[0034] Preferably, the expression vector promoter is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV;
[0035] Preferably, the shRNA-AHF expression vector connected thereto is selected from: a recombinant adeno-associated virus expression vector pAAV-D(+)-shRNA-AHF connected thereto with a shRNA-AHF sequence; or a recombinant adeno-associated virus expression vector pAAV-D(+)-tnt-shRNA-AHF connected thereto with a myocardial-specific promoter tnt and a shRNA-AHF sequence in sequence;
[0036] Preferably, the host cell of the transformant is selected from: 293 cells;
[0037] Preferably, the transformant transformed with the shRNA-AHF expression vector is selected from: a recombinant adeno-associated virus rAAV-shRNA-AHF transformed with a recombinant adeno-associated virus expression vector pAAV-D(+)-shRNA-AHF; or a recombinant adeno-associated virus rAAV-tnt-shRNA-AHF transformed with a recombinant adeno-associated virus expression vector pAAV-D(+)-tnt-shRNA-AHF;
[0038] Preferably, the shRNA-AHF sequence is shown as SEQ ID NO.1;
[0039] A recombinant expression vector having the effect of treating heart failure, characterized in that it is an expression vector connected to the sequence of the gene having the effect of treating heart failure.
[0040] The expression vector is selected from: an adeno-associated virus expression vector pAAV-D(+);
[0041] Preferably, the recombinant expression vector having the effect of treating heart failure is selected from: a recombinant adeno-associated virus expression vector pAAV-D(+)-shRNA-AHF connected to a shRNA-AHF gene sequence.
[0042] A transformant with the effect of treating heart failure, characterized in that it is a host cell transformed with the recombinant expression vector with the effect of treating heart failure.
[0043] The host cell is selected from: 293 cells;
[0044] Preferably, the transformant having the effect of treating heart failure is selected from: a recombinant adeno-associated virus rAAV-shRNA-AHF transformed with a recombinant adeno-associated virus expression vector pAAV-D(+)-shRNA-AHF1. Or, a recombinant adeno-associated virus rAAV-tnt-shRNA-AHF transformed with a recombinant adeno-associated virus expression vector pAAV-D(+)-tnt-shRNA-AHF;
[0045] Furthermore, the drug also includes pharmaceutically acceptable adjuvants and / or reagents for buffering, synthesizing, and / or purifying the sequence fragments. Those skilled in the art can add various pharmaceutically acceptable adjuvants / adjuvants to the anti-heart failure drug of the present invention according to objective needs to prepare various dosage forms for easy sale or promotion.
[0046] In a further embodiment, the preparation method comprises: inserting the shRNA-AHF sequence fragment into an expression vector, thereby preparing a recombinant plasmid that can stably express shRNA-AHF.
[0047] In a specific embodiment, the expression vector containing the shRNA-AHF sequence fragment is an adeno-associated virus expression vector pAAV-D(+).
[0048] In order to achieve the purpose of gene therapy for heart failure, the present invention recombined the shRNA-AHF sequence fragment with a recombinant adeno-associated virus vector, and obtained a high titer that meets the treatment requirements after detection, and confirmed in animal experiments that it can effectively improve the cardiac function of mice with heart failure. Therefore, based on the above findings and results, the present invention provides a small RNA drug represented by shRNA-AHF for the treatment of clinical heart failure.
[0049] The present invention relates to a drug for treating heart failure. The anti-heart failure drug relates to the construction and preparation method of a recombinant adeno-associated virus recombinant (rAAV-shRNA-AHF) of shRNA-AHF, and the drug effect of treating heart failure is achieved by high expression of the rAAV-shRNA-AHF. The present invention utilizes a chemical synthesis method to construct a pAAV-D(+)-shRNA-AHF expression plasmid, and utilizes a three-plasmid calcium phosphate co-transfection method to package and prepare a recombinant adeno-associated virus containing a target fragment and purify it. Animal experiments have confirmed that the anti-heart failure drug provided by the present invention can significantly improve the cardiac function of animals with heart failure and play an effective anti-heart failure role.
[0050] The present invention designs and synthesizes the sequence of shRNA-AHF, and successfully inserts it into the eukaryotic expression vector pAAV-D(+) to form the recombinant plasmid pAAV-D(+)-shRNA-AHF. Afterwards, the following three plasmids: 1) pXX9 plasmid, 2) phelper plasmid, 3) pAAV-D(+)-shRNA-AHF plasmid, are respectively transferred into 293 cells by calcium-phosphate co-transfection method to package and prepare recombinant adeno-associated virus (rAAV9) that can express shRNA-AHF. After purification, the titer is determined by real-time PCR. In the next step, the recombinant adeno-associated virus (rAAV-shRNA-AHF) of the same serotype prepared by packaging is injected into the heart failure model mice caused by aortic ligation (TAC) through the tail vein. Ultrasound and catheter results show that shRNA-AHF mediated by recombinant adeno-associated virus can significantly improve the cardiac function of TAC mice. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0052] Figure 1 Experimental Example 1 of the present invention involves the regulatory effect of the screened shRNA sequence on the myocardial hypertrophy marker ANP.
[0053] Figure 2 It is a schematic diagram of the structure of the plasmid pAAV-D(+)-shRNA-AHF prepared in Experimental Example 1 of the present invention; wherein, the tnt promoter represents a cardiomyocyte-specific promoter.
[0054] Figure 3 This is the effect of rAAV-shRNA-AHF treatment on the cardiac function of TAC mice monitored by cardiac ultrasound and catheter in Experimental Example 2 of the present invention, wherein A is a bar graph of ejection fraction, B is a bar graph of shortening fraction, C is a bar graph of the maximum rate of increase of left ventricular pressure during isovolumetric contraction, and D is a bar graph of the minimum rate of increase of left ventricular pressure during isovolumetric contraction; the results show that rAAV-shRNA-AHF can significantly increase the cardiac contractile and diastolic functions of TAC mice.
[0055] The meanings of the symbols in the figure are listed as follows: rAAV-shNC represents TAC mice injected with a recombinant adeno-associated virus vector expressing a control shRNA that specifically targets cardiomyocytes; rAAV-shRNA-AHF represents TAC mice injected with a recombinant adeno-associated virus vector expressing shRNA-AHF that specifically targets cardiomyocytes; sham represents sham-operated control mice; and TAC represents TAC-induced heart failure model mice. DETAILED DESCRIPTION
[0056] The technical solution of the present invention will be clearly and completely described below in conjunction with specific embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0057] The sources of the instruments, equipment, reagents, consumables and biological materials involved in the following embodiments or experimental examples are as follows:
[0058] 1) Instruments and Equipment
[0059] ND-1000 nucleic acid analyzer, ABI 9700PCR instrument, ABI 7900HT fluorescence real-time quantitative PCR instrument, Beckman X-15R low-temperature high-speed centrifuge;
[0060] 2) Reagents and consumables
[0061] RNasey Mini Kit (purchased from Qiagen), TRIZOL (purchased from Invitrogen), TaKaRa Agarose Gel DNA Purification Kit Ver.2.0 (agarose gel DNA recovery kit, purchased from TaKaRa), Endo-Free Plasmid Maxi Kit (plasmid extraction kit, purchased from OMEGA), EasyPure Plasmid MiniPrep Kit (plasmid extraction kit, purchased from Beijing Quanshijin Company); eukaryotic expression vector pAAV-D(+) was constructed and donated by Professor Xiao Xiao, a cooperator, and the core sequences of shRNA-1, shRNA-2, shRNA-3, shRNA-4 and shRNA-5 were synthesized by Sangon Biotech (Shanghai) Co., Ltd. The pAAV-shRNA-AHF sequence fragment was synthesized by Wuhan Corester Biotech Co., Ltd.
[0062] Sources of biological materials
[0063] C57 mice were purchased from Beijing Huafukang Company;
[0064] 293T cells were from ATCC, USA.
[0065] Group 1 Example, shRNA of the present invention
[0066] This group of embodiments provides a shRNA. All embodiments in this group have the following common features: the DNA sequence corresponding to the shRNA is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0067] In some embodiments, the shRNA is shRNA-AHF, and its corresponding DNA sequence is SEQ ID NO.1.
[0068] In some embodiments, the shRNA is shRNA-3, and its corresponding DNA sequence is SEQ ID NO.3.
[0069] In other embodiments, the shRNA is shRNA-5, and its corresponding DNA sequence is SEQ ID NO.5.
[0070] The above shRNA-AHF (shRNA-1), shRNA-3 and shRNA-5 can reduce the expression of ANP, a marker of myocardial hypertrophy (shRNA-1 has the most obvious effect). Among them, shRNA-3 and shRNA-5 target human sequences and cannot be used for mouse experiments. At the same time, due to time constraints, human clinical trials cannot be carried out in the short term, so only the results of myocardial cell experiments can be provided (such as Figure 1 ), proving that they have the function of protecting cardiomyocytes.
[0071] The above-mentioned shRNAs are all designed and synthesized for the first time by the present invention. Any act of amplifying, synthesizing, producing, manufacturing, selling, offering for sale, using, importing, exporting, secreting, multiplying, enriching, connecting, transforming, cloning, and expressing any of the above-mentioned shRNAs, and / or any act of using any of the above-mentioned shRNAs for pharmaceutical preparation or as a drug ingredient, and / or any act of using any of the above-mentioned shRNAs for treatment falls within the scope of protection of the present invention.
[0072] The second group of embodiments, the recombinant expression vector of the present invention
[0073] This group of embodiments provides a recombinant expression vector. All embodiments in this group have the following common features: the recombinant expression vector is an expression vector connected with shRNA; the DNA sequence corresponding to the shRNA is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0074] In a specific embodiment, the promoter of the expression vector is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV;
[0075] Preferably, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
[0076] The above-mentioned recombinant expression vectors are all prepared for the first time by the present invention. Any act of amplifying, synthesizing, producing, manufacturing, selling, offering for sale, using, importing, exporting, secreting, multiplying, enriching, connecting, transforming, cloning, and expressing the above-mentioned recombinant expression vectors, and / or any act of using the above-mentioned recombinant expression vectors for pharmaceutical preparation or as drug ingredients, and / or any act of using the above-mentioned recombinant expression vectors for treatment falls within the scope of protection of the present invention.
[0077] The third group of examples, transformants of the present invention
[0078] This group of embodiments provides a transformant. All embodiments in this group have the following common features: the transformant is a host transformed with a recombinant expression vector; the recombinant expression vector is an expression vector connected with shRNA; the DNA sequence corresponding to the shRNA is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0079] In some embodiments, the host is selected from: a virus, and / or a cell;
[0080] Preferably, the virus is selected from adeno-associated virus;
[0081] Preferably, the cells are selected from 293 cells;
[0082] Preferably, the promoter of the expression vector is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV;
[0083] Preferably, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
[0084] The above-mentioned transformants are all prepared for the first time by the present invention. Any act of amplifying, synthesizing, producing, manufacturing, selling, offering for sale, using, importing, exporting, secreting, multiplying, enriching, connecting, transforming, cloning, expressing the above-mentioned transformants, and / or any act of using the above-mentioned transformants for pharmaceutical preparation or as a drug ingredient, and / or any act of using the above-mentioned transformants for treatment falls within the scope of protection of the present invention.
[0085] The fourth group of embodiments, the anti-heart failure drug of the present invention
[0086] This group of embodiments provides an anti-heart failure drug. All embodiments in this group have the following common features: the anti-heart failure drug includes a pharmacologically active ingredient, and the pharmacologically active ingredient includes: a shRNA whose corresponding DNA sequence is selected from SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0087] In some embodiments, the pharmacologically active ingredient is selected from the group consisting of: shRNA, recombinant expression vector, and transformant;
[0088] The shRNA has the sequence shown in SEQ ID NO.1; the transformant is a host containing a recombinant expression vector; the recombinant expression vector is an expression vector connected to the shRNA with the sequence shown in SEQ ID NO.1;
[0089] Preferably, the anti-heart failure drug further comprises: pharmaceutical excipients; and / or reagents for amplifying, synthesizing, producing, manufacturing, selling, offering for sale, using, importing, exporting, secreting, multiplying, enriching, connecting, transforming, cloning, expressing the shRNA described in any one of the first group of embodiments, and / or the recombinant expression vector described in any one of the second group of embodiments, and / or the transformant described in any one of the third group of embodiments;
[0090] Based on the teachings of the present invention, those skilled in the art can add various pharmaceutically acceptable adjuvants / excipients to the anti-heart failure drugs of the present invention according to production needs and practical requirements to prepare various dosage forms for easy sale or promotion.
[0091] In a specific embodiment, the pharmaceutical excipient is selected from: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids, and release retardants.
[0092] Preferably, the promoter of the expression vector is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV;
[0093] Preferably, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
[0094] The fifth group of embodiments, the preparation method of the anti-heart failure drug of the present invention
[0095] This group of embodiments provides a method for preparing an anti-heart failure drug. All embodiments in this group have the following common features: preparing shRNA; and the DNA sequence corresponding to the shRNA is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0096] In a specific embodiment, the preparation is selected from the group consisting of synthesis, amplification, expression, cloning, secretion, enrichment, and expansion;
[0097] Preferably, the synthesis refers to whole gene synthesis technology;
[0098] Preferably, the cloning refers to connecting the shRNA to an expression vector;
[0099] Preferably, the promoter of the expression vector is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV;
[0100] Preferably, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
[0101] In a further embodiment, the preparation method further comprises: combining or mixing the pharmaceutically active ingredient with a pharmaceutical excipient.
[0102] Based on the teachings of the present invention, those skilled in the art can add various pharmaceutically acceptable adjuvants / excipients to the anti-heart failure drugs of the present invention according to production needs and practical requirements to prepare various dosage forms for easy sale or promotion.
[0103] In a specific embodiment, the pharmaceutical excipient is selected from: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids, and release retardants.
[0104] Group 5 Example: Pharmaceutical Use of shRNA of the Present Invention
[0105] This group of embodiments provides the use of shRNA in preparing anti-heart failure drugs. All embodiments in this group have the following common features: the DNA sequence corresponding to the shRNA is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5.
[0106] In some embodiments, the anti-heart failure drug uses shRNA or a recombinant expression vector or transformant as a pharmacologically active ingredient;
[0107] In a further embodiment, the anti-heart failure drug further comprises a pharmaceutical excipient;
[0108] In a specific embodiment, the pharmaceutical excipient is selected from: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids, and release retardants.
[0109] In a specific embodiment, the transformant is a host containing a recombinant expression vector; the recombinant expression vector is an expression vector connected to the shRNA sequence shown in SEQ ID NO.1, which can play a role in treating heart failure;
[0110] In a preferred embodiment, the promoter of the expression vector is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV;
[0111] Preferably, the expression vector is selected from adeno-associated virus expression vector pAAV D(+);
[0112] Preferably, the host is selected from: viruses, and / or cells;
[0113] Preferably, the virus is selected from adeno-associated virus;
[0114] Preferably, the cells are selected from 293 cells.
[0115] The present invention is further described below with examples:
[0116] Experimental Example 1: Construction of recombinant adeno-associated virus
[0117] 1. shRNA-AHF sequence screening
[0118] During the preliminary screening process, the applicant designed several shRNAs with potential anti-heart failure effects, as shown in SEQ ID NO.1 to SEQ ID NO.5. The core sequence of shRNA was synthesized by Sangon Biotech (Shanghai) Co., Ltd. After cell experiment screening, it was found that shRNA-1 (i.e. shRNA-AHF) containing the sequence of SEQ ID NO.1 had the most significant effect in reducing the hypertrophy marker ANP (shRNA-3 and shRNA-5 can also reduce ANP) ( Figure 1 ). The applicant further selected SEQ ID NO.1 for animal experiments as a representative of the embodiment. The constructions described below are only some embodiments of the present invention. For those of ordinary skill in the art, similar embodiment results can also be obtained based on these shRNA sequences without creative work.
[0119] 2. Construction of pAAV-D(+) vector
[0120] The rAAV-shRNA-AHF double-stranded nucleotide was synthesized by full gene synthesis technology and cloned into the pAAV-D(+) vector ( Figure 2 ), double-stranded nucleotides were synthesized by Wuhan Crester Biotechnology Co., Ltd. The sequence of shRNA-AHF is shown in SEQ ID NO.1.
[0121] 3. Plasmid Transformation
[0122] Add pAAV-D(+)-shRNA-AHF plasmid to 100 μl DH5α competent cells and place in ice for 30 min; heat at 42°C for 45 sec, and place in ice for 1 min; add 500 μl antibiotic-free LB medium, shake and culture at 37°C and 100 rpm for 60 min; culture on Amp+ LB plate medium, and select white monoclonal colonies for identification.
[0123] 4. Plasmid extraction
[0124] Pick a single clone colony and add it to 3 ml of LB liquid medium containing Amp+, and culture it at 37°C with shaking at 280 rpm overnight. Kit was used to extract plasmid. The specific steps are as follows: 1. Take 1.5 ml of overnight cultured bacteria and centrifuge at 10,000g for 1 min, and try to remove the supernatant; 2. Add 250μl of colorless solution RB (containing RNaseA) and oscillate to suspend the bacterial precipitate; 3. Add 250μl of blue solution LB, gently invert and mix 4-6 times to fully lyse the bacteria and form a blue transparent solution; 4. Add 350μl of yellow solution NB, gently mix 5-6 times until a compact yellow agglomerate is formed, and let stand at room temperature for 2 min; 5. Centrifuge at 15,000g for 5 min, carefully aspirate the supernatant and add it to the adsorption column; 6. Centrifuge at 15,000g for 1 min, and discard the effluent; 7. Add 650μl of solution WB, centrifuge at 15,000g for 1 min, and discard the effluent; 8. Centrifuge at 15,000g for 2 min to completely remove the residual WB; 9. Place the adsorption column in a new Ep tube and add 20μl Preheat EB at 70°C and let stand at room temperature for 1 min; centrifuge at 10,000 g for 1 min to elute DNA, and store the eluted DNA at -20°C.
[0125] 5. Plasmid extraction
[0126] Prepare a 1L sterile conical flask, add 300ml sterile LB medium, and add ampicillin solution to a final concentration of 100μg / ml. Add 50μl of the required plasmids (pXX9, phelper, pAAV-D(+)-shNC, pAAV-D(+)-shRNA-AHF) respectively, and culture overnight at 280rpm and 37℃. Follow the instructions of OMEGA's Endo-Free Plasmid Maxi Kit to extract the plasmid. The specific steps are as follows: 1. Centrifuge at 5000g for 10 minutes at room temperature to collect bacteria; 2. Discard the culture medium, add 10ml Solution I / RNase A mixture, and vortex to completely resuspend; 3. Add 10ml Solution II to the resuspended mixture, gently invert and mix 10-15 times, and place at room temperature.
[0127] 6. rAAV-mediated viral packaging
[0128] 293T cells grow to 90%, 1-2 hours before calcium-phosphorus transfection, each culture dish is replaced with 12-15 ml of fresh culture medium (containing serum), calcium chloride (CaCl2) is first added to a 50 ml centrifuge tube, and then plasmid is added to form a Ca-DNA mixed solution, which is fully mixed, and 2XHEBS BUFFER is slowly added to the Ca-DNA mixed solution to form a Ca-DNA-P mixed solution, while adding 2X HEBS, the centrifuge tube is shaken, and fully mixed to form calcium-phosphorus particles. After 8-12 hours, 18-20 ml of serum-free culture medium is replaced, and after 72 hours, the culture medium is aspirated and washed 3 times with PBS, 1 ml of Tris+NaCl (pH 8.5) is added to each culture dish, and cells are scraped with a scraper, collected in a clean centrifuge tube, and frozen at -80°C.
[0129] 7. Virus Purification
[0130] Take out the cells frozen at -80℃, thaw and dissolve at 37℃, repeat freezing and thawing 4 times, centrifuge at 8,000g for 15min, put the supernatant into a clean centrifuge tube, and discard the cell pellet. Mix the rAAV with -20℃ pre-cooled anhydrous ethanol at a volume ratio of 3:1, place in a -20℃ refrigerator for 2hr, centrifuge at 4℃, 13,000rpm for 15min, and discard the supernatant; after the ethanol evaporates, add the corresponding volume of Tris+NaCl (pH 8.5) to dissolve the precipitate. Filter with a Millipore small filter (0.22μm).
[0131] 8. Virus Titer Determination
[0132] Sample processing:
[0133] rAAV virus solution 40μl
[0134] Proteinase K (20 mg / ml) 5 μl
[0135] 55°C, reaction for 1 hr;
[0136] Phenol:chloroform:isoamyl alcohol 45 μl
[0137] The aqueous phase was recovered by centrifugation at 12,000 g for 5 min at 4°C;
[0138] Chloroform 45 μl
[0139] The aqueous phase was recovered by centrifugation at 12,000 g for 5 min at 4°C.
[0140] Real-time PCR:
[0141] Primer 1 (10 μm) 0.4 μl
[0142] Primer 2 (10 μm) 0.4 μl
[0143] SYBR Green I Mix 10 μl
[0144] dH 2 O 8.2 μl
[0145] Template 1μl
[0146] 95℃30sec---(95℃5sec---60℃5sec---72℃20sec)×40 cycles---MeltingCurve Experimental Example 2: Using rAAV9 type recombinant adeno-associated virus expressing shRNA-AHF as an example to detect its therapeutic effect on heart failure
[0147] Eight-week-old C57 mice were injected with rAAV-tnt-shRNA-AHF and control rAAV-tnt-shNC viruses through the tail vein, with a virus titer of 1×10 11PFU / each, TAC surgery was performed 2 weeks later: Transverse Aortic Constriction (TAC), and the cardiac function of mice was tested at the end of the experiment (4 weeks later), the method is as follows: the instrument used is an ultrasound machine equipped with a 30MHz high-frequency probe. After the mice were anesthetized with isoflurane, they were placed supine on the detection platform. Two-dimensional images of the left ventricle were collected along the short-axis and long-axis sections at the level of the left ventricular papillary muscle beside the sternum of the mice. At the same time, more than 5 continuous cardiac cycle M-mode ultrasound images were obtained under the guidance of two-dimensional images. According to the results of the collected images, the cardiac hemodynamic indicators of cardiac ultrasound detection were obtained. The following indicators were calculated after analysis by relevant software: including heart rate (HR), left ventricular internal dimension (diastole, LVIDd), left ventricular internal dimension (systole, LVIDs), left ventricular posterior wall diastole thickness (diastole, LVPWd), left ventricular posterior wall systole thickness (LVPWs), interventricular septal thickness (diastole, IVSd), interventricular septal thickness (systole, L ... thickness, systole, IVSs), ejection fraction (EF) and fractional shortening (FS). The results showed that rAAV-shRNA-AHF treatment could significantly improve the cardiac function of TAC mice ( Figure 3 ).
Claims
1. A shRNA, characterized in that The corresponding DNA sequence is selected from: SEQ ID NO.1, SEQ ID NO.3 or SEQ ID NO.
5.
2. A recombinant expression vector, characterized in that: It is an expression vector connected with shRNA; the DNA sequence corresponding to the shRNA is selected from: SEQ ID NO.1, SEQ ID NO.3 or SEQ ID NO.
5.
3. A recombinant expression vector according to claim 2, characterized in that: The promoter of the expression vector is selected from: cardiomyocyte-specific promoters tnt, α-MHC, MLC-2v, Desmin, or non-specific promoters H1, U6, CMV; And / or, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
4. A transformant, characterized in that: The host is transformed with a recombinant expression vector; the recombinant expression vector is an expression vector connected with shRNA; the DNA sequence corresponding to the shRNA is selected from: SEQ ID NO.1, SEQ ID NO.3 or SEQ ID NO.
5.
5. A transformant according to claim 4, characterized in that The host is selected from: viruses, and / or cells; and / or, the virus is selected from adeno-associated virus; And / or, the cells are selected from 293 cells; And / or, the promoter of the expression vector is selected from: cardiomyocyte-specific promoter tnt, α-MHC, MLC-2v, Desmin, or non-specific promoter H1, U6, CMV; And / or, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
6. An anti-heart failure drug, comprising a pharmacologically active ingredient, characterized in that: The pharmaceutically active ingredient includes: shRNA whose corresponding DNA sequence is SEQ ID NO.
1.
7. An anti-heart failure drug according to claim 6, characterized in that: The pharmacologically active ingredient is selected from: shRNA, recombinant expression vector or transformant; The DNA sequence corresponding to the shRNA is the sequence shown in SEQ ID NO.1; the transformant is a host containing a recombinant expression vector; the recombinant expression vector is an expression vector connected to the shRNA sequence shown in SEQ ID NO.1; And / or, the anti-heart failure drug further comprises: pharmaceutical excipients; And / or, the promoter of the expression vector is selected from: cardiomyocyte-specific promoter tnt, α-MHC, MLC-2v, Desmin, or non-specific promoter H1, U6, CMV; And / or, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
8. A method for preparing an anti-heart failure drug, characterized in that: Prepare shRNA; the DNA sequence corresponding to shRNA is SEQ ID NO.
1.
9. The method for preparing an anti-heart failure drug according to claim 8, characterized in that: The preparation includes: synthesis, amplification, expression, cloning, secretion, enrichment or expansion; And / or, the synthesis refers to whole gene synthesis technology; And / or, the cloning refers to connecting the shRNA to an expression vector; And / or, the promoter of the expression vector is selected from: cardiomyocyte-specific promoter tnt, α-MHC, MLC-2v, Desmin, or non-specific promoter H1, U6, CMV; And / or, the expression vector is selected from adeno-associated virus expression vector pAAV D(+).
10. Use of shRNA in the preparation of an anti-heart failure drug, characterized in that: The DNA sequence corresponding to shRNA is SEQ ID NO.1.
